CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage

NCT05333874 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer, Early-Onset

Interventions

DRUG: Neoadjuvant chemotherapy administered before surgical extraction of a tumor
OTHER: Observational

Sponsor

Rutgers, The State University of New Jersey